Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$1,318.96

0.51 (0.04%)

, GOOGL

Alphabet Class A

$1,318.08

-2.09 (-0.16%)

12:19
11/19/19
11/19
12:19
11/19/19
12:19

'Big Tech' firms 'defend' themselves in responses to regulators, Reuters says

Alphabet's Google (GOOG,GOOGL), Facebook (FB), Amazon (AMZN) and Apple (AAPL), responded to questions from the House of Representatives Judiciary Committee, with a mixture of defending their practices and declining to give answers, says Reuters. "The companies, long a symbol of the most dynamic aspect of the U.S. economy, have seen their reputations tarnished by privacy lapses and allegations they abused their perch on top of the market to hurt small and nascent rivals," added the Reuters' story. Reference Link

GOOG

Alphabet

$1,318.96

0.51 (0.04%)

GOOGL

Alphabet Class A

$1,318.08

-2.09 (-0.16%)

FB

Facebook

$199.25

1.8 (0.91%)

AMZN

Amazon.com

$1,753.39

0.69 (0.04%)

AAPL

Apple

$266.15

-0.88 (-0.33%)

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

GOOG Alphabet
$1,318.96

0.51 (0.04%)

11/11/19
UBSW
11/11/19
NO CHANGE
Target $240
UBSW
Buy
Nvidia price target raised to $240 ahead of earnings, DC product launch at UBS
UBS analyst Timothy Arcuri raised his price target on Nvidia shares to $240 from $195 ahead of the company's October quarter earnings report. He models quarterly revenue and EPS of $2.91B and $1.61, respectively, which he notes is "more or less" in-line with consensus, but he still sees a path higher for the stock despite the fact that it has outperformed both the S&P 500 and S&P 500 Semis by a "wide margin" over the last three months. Data is starting to play out to prove strength in gaming as ray tracing becomes standard and in the data center as the new 7nm product should be announced next week, said Arcuri. He thinks "performance-focused" customers like Google (GOOGL) are waiting for this new 7nm product and that others are building it into their 2020 roadmaps, the analyst added.
11/19/19
BTIG
11/19/19
NO CHANGE
BTIG
Neutral
GrubHub needs to get more efficient with marketing costs, says BTIG
BTIG analyst Peter Saleh keeps his Neutral rating on GrubHub (GRUB), noting that while the healthy consumer demand for quick delivery service in fast-casual and casual dining categories should survive, providers will need to be "more efficient" with their advertising budgets. The analyst adds that the expected migration toward delivery aggregators such as FoodBoss or Google (GOOG) will be positive for GrubHub's value offering, but he remains on the sidelines until he sees a reversal in the company's diner acquisition costs, increase in customer frequency, or a stronger financial outlook.
11/07/19
PIPR
11/07/19
NO CHANGE
Target $39
PIPR
Neutral
TripAdvisor price target lowered to $39 from $52 at Piper Jaffray
Piper Jaffray analyst Michael Olson lowered his price target for TripAdvisor (TRIP) shares to $39 from $52 after the company reported weak Q3 revenue and EBITDA and lowered its FY19 EBITDA growth expectation. He believes Google's (GOOGL) "increased aggressiveness" in travel, including placing more emphasis on its own hotel offerings and driving free links farther down the page, is hurting TripAdvisor as well as other online travel players, Olson tells investors. TripAdvisor, and others, may have to turn to higher cost marketing channels to drive similar traffic or face further top-line challenges, contends the analyst, who keeps a Neutral rating on the TripAdvisor shares.
11/14/19
RHCO
11/14/19
NO CHANGE
Target $43
RHCO
Buy
TripAdvisor price target lowered to $43 from $60 at SunTrust
SunTrust analyst Naved Khan lowered his price target on TripAdvisor (TRIP) to $43 after its Q3 earnings miss reported last week. The analyst says he was mistaken in expecting stabilization in the company's Hotels, Media & Platform segment and also underestimated the SEO risk from Google (GOOGL). Khan is keeping his Buy rating on TripAdvisor stock however, stating that its Experiences/Dining business accounts for the "bulk" of its intrinsic value and represents the primary reason to hold the shares.
GOOGL Alphabet Class A
$1,318.08

-2.09 (-0.16%)

11/08/19
DADA
11/08/19
NO CHANGE
Target $44
DADA
Buy
TripAdvisor price target lowered to $44 from $55 at DA Davidson
DA Davidson analyst Tom White lowered his price target on TripAdvisor (TRIP) to $44 after its "disappointing" Q3 results as the company's core Hotels, Media & Platform segment revenue fell 12% while leading to a cut in its 2019 EBITDA growth outlook to "single-digits" from "double-digit". The analyst notes that the competitive Google (GOOGL) SEO issues are unlikely to abate in 2020, but he is keeping his Buy rating on the stock, noting that Tripadvisor is making progress in accelerating its ongoing transformation into a hotel/lodging business that relies less on auction-based ad spend.
11/11/19
LOOP
11/11/19
NO CHANGE
Target $1450
LOOP
Hold
Alphabet price target raised to $1,450 from $1,350 at Loop Capital
Loop Capital analyst Alan Gould raised his price target on Alphabet to $1,450, rolling forward his valuation model to 2021 and noting that the company's fundamentals remains strong while its growth in advertising revenue continues at unprecedented scale. The analyst is keeping his Hold rating on Alphabet however, stating that the current regulatory environment poses a growing challenge with no expected improvement over the next 12 months.
FB Facebook
$199.25

1.8 (0.91%)

11/15/19
JPMS
11/15/19
NO CHANGE
JPMS
Overweight
JPMorgan adds Lyft to list of top Internet picks
Earlier, JPMorgan analyst Doug Anmuth added Lyft (LYFT) to his list of top picks in the internet sector following third quarter earnings, saying the ride-hailing giant reported "significantly" better than expected revenue and EBITDA as it continues to take share of an increasingly rational U.S. rideshare market, thereby accelerating its path to profitability. Anmuth said that Lyft, which joins Facebook (FB), Amazon (AMZN), and Netflix (NFLX) in his top picks in the sector, also reiterated its expectation for consolidated EBITDA profit by the fourth quarter of 2021, though he continues to believe core rideshare can be profitable "well before that," likely sometime in 2020. The analyst, who has an Overweight rating on Lyft, noted that he removed Twitter (TWTR) and IAC/InterActive (IAC) from his top picks.
11/04/19
DAIW
11/04/19
UPGRADE
DAIW
Buy
Facebook upgraded to Buy from Outperform at Daiwa
11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
DAIW
11/05/19
UPGRADE
Target $250
DAIW
Buy
Daiwa upgrades Facebook to Buy, says earnings concerns 'largely alleviated'
Daiwa analyst Satoshi Tanaka last night upgraded Facebook to Buy from Outperform with a price target of $250, up from $235. The company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns," Tanaka tells investors in a research note. The analyst sees "clearer visibility" from 2020 as well as higher upside after the stock's recent pullback. Facebook's revenue growth slowdown is more moderate than previously anticipated while its guidance for total expenses remains within expectations, contends the analyst. He believes the "negative repercussions" stemming from the implementation of Europe's new data protection regulation and Facebook's data leak "controversy are clearer now that a year has passed." Concerns on the earnings front "have largely been alleviated," says Tanaka.
AMZN Amazon.com
$1,753.39

0.69 (0.04%)

11/19/19
WBLR
11/19/19
NO CHANGE
WBLR
Outperform
Kornit sales beat when adjusting for Amazon warrants, says William Blair
William Blair analyst Brian Drab says Kornit Digital (KRNT) reported "another impressive quarter." Kornit's Q3 results were ahead of expectations, contrary to the negative headlines immediately following the report, which were again based on misinterpretation of results given the impact of Amazon warrants (AMZN), Drab tells investors in a post-earnings research note. Adjusting correctly for the warrants, the company's Q3 revenue increased 27%, to $49.7M, ahead of the consensus estimate of $48.7M, adds the analyst. He expects Kornit to continue to generate greater than 20% revenue growth and keeps an Outperform rating on the shares.
11/18/19
DADA
11/18/19
INITIATION
Target $55
DADA
Neutral
Crowdstrike valuation appropriately balances upside potential, says DA Davidson
As reported earlier, DA Davidson Andrew Nowinski initiated coverage of Crowdstrike (CRWD) with a Neutral rating and $55 price target, saying the company is generating "unmatched" ARR growth, driven by sustainable, competitive advantages from a cloud-based platform. Nowinski said he believes the Amazon Web services (AMZN) partnership is seeing increasing momentum and the company has the potential to expand margins longer-term. The analyst noted, however, that he believes the current valuation appropriately balances the upside potential from these drivers.
11/19/19
ADAM
11/19/19
NO CHANGE
Target $70
ADAM
Buy
Canaccord says 'stay the course' with Five9 after Salesforce Cloud Voice reveal
Canaccord analyst David Hynes Jr. noted that Salesforce (CRM) revealed Service Cloud Voice, which is expected to be in pilot by February 2020 and generally available in June 2020, at its Dreamforce event. While it's unclear at this point what impact, if any, this could have on Salesforce's enterprise referral relationship with Five9 (FIVN) and he is not surprised to see the latter trading modestly lower today, Hynes Jr. recommends investors "stay the course" with Five9. To support his call for patience, Hynes Jr. stated that Five9 is "undeniably a leader" in delivering integrated telephony capabilities in the cloud, said that Salesforce's chosen out-of-the-box telephony partner, Amazon Connect, has "proven to date to have had little traction in enterprise markets," and argued that similar announcements from Five9 partners in the past - such as Zendesk Talk powered by Twilio - have had little impact on Five9's enterprise momentum. He keeps a Buy rating and $70 price target on Five9 shares, which are down 3% to $62.76 at time of writing.
AAPL Apple
$266.15

-0.88 (-0.33%)

11/19/19
FBCO
11/19/19
NO CHANGE
Target $221
FBCO
Neutral
Apple's iPhone unit trends remain 'solid,' says Credit Suisse
Credit Suisse analyst Matthew Cabral tells investors in a research note that nearly two months into the iPhone 11 cycle, data points continue to suggest a meaningful improvement in units y/y. Government data suggests iPhone units are up 6% y/y in China over September and October combined, with Cabal adding that his firm's tracking data suggesting the iPhone has yet to hit full supply/demand balance eight weeks post-launch. While Cabral says he is "on board" with the idea that the shift toward Services deserves a higher multiple over time, he "struggles" with continued P/E expansion seemingly led by firming iPhone data points rather than Services-driven upside. The analyst keeps a Neutral rating and $221 price target on Apple shares.
11/19/19
WEDB
11/19/19
NO CHANGE
Target $325
WEDB
Outperform
China the 'linchpin' of success on Apple iPhone supply chain, says Wedbush
Wedbush analyst Daniel Ives tells investors in a research note that President Trump is expected to visit Apple's tech manufacturing facility in Austin, Texas along with CEO Tim Cook in what he calls a key strategic visit for the company. While Ives says he sees more AI and hardware manufacturing coming out of the U.S., India, and potentially Vietnam down the road, for the foreseeable future China remains the "linchpin" of success on the iPhone supply chain with Cook needing to "play nice in the sandbox" both in the U.S. as well as in China to make sure no new roadblocks appear that could derail this potential "5G super cycle" heading into 2020. He keeps an Outperform rating and $325 price target on Apple shares.
11/18/19
SOCG
11/18/19
NO CHANGE
Target $200
SOCG
Sell
Societe Generale sees big downside in Netflix shares with 'uniqueness' eroding
A "wider competitive set" has started to dilute Netflix's (NFLX) perceived "uniqueness" and will probably restrain its pricing power in the short term, Societe Generale analyst Christophe Cherblanc tells investors in a research note. The low price points set by Disney+ (DIS) at $6.99 per month and Apple TV+ (AAPL) at $4.99 per month will likely make Netflix more cautious exercising its pricing power, Cherblanc contends. Further, he believes the company's 2019 price increases have had a slightly higher than expected impact on U.S. churn. The analyst keeps a Sell rating on Netflix with a $200 price target. The streaming service closed Friday up $5.41 to $295.03. Despite the recent pullback, the shares still have "significant downside" risk, Cherblanc contends. Nonetheless, the analyst thinks Netflix will retain a dominant position in a "rapidly expanding" over-the-top market and deliver steady margin expansion.
11/15/19
JPMS
11/15/19
NO CHANGE
Target $290
JPMS
Overweight
JPMorgan ups Apple target to $290 on 'underappreciated' advertising opportunity
JPMorgan analyst Samik Chatterjee raised his price target for Apple to $290 from $280 and reiterates an Overweight rating on the shares. Following the stock's strong run, investor attention is increasingly focusing on identifying new avenues of Services revenue growth beyond the current ventures, such as Apple Music, Apple Pay, Apple Arcade, and its latest, Apple TV+, "which are still very much in early innings," Chatterjee tells investors in a research note. However, he believes "hidden in plain sight and underappreciated by most" is Apple's advertising opportunity. The analyst highlights the "secular migration" of advertising dollars to mobile platforms and Apple's large installed base of close to 1B iPhone users. Chatterjee estimates that if Apple were willing to accelerate monetization of advertising through an expansion of its current efforts with Apple Search Ads as well as adopting new strategies around Apple TV, it could expand advertising revenues 33% per annum to $11B in fiscal 2020 from an estimated ~$2B currently. Piper Jaffray this morning also raised its price target on Apple to $290.

TODAY'S FREE FLY STORIES

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.